Aclaris Therapeutics Inc (ACRS)

$1.19

-0.02

(-1.65%)

Market is closed - opens 8 PM, 26 Feb 2024

Performance

  • $1.17
    $1.24
    $1.19
    downward going graph

    1.68%

    Downside

    Day's Volatility :5.65%

    Upside

    4.03%

    downward going graph
  • $0.59
    $12.93
    $1.19
    downward going graph

    50.4%

    Downside

    52 Weeks Volatility :95.44%

    Upside

    90.8%

    downward going graph

Returns

PeriodAclaris Therapeutics Inc
3 Months
36.8%
6 Months
-82.75%
1 Year
-90.18%
3 Years
-94.39%

Highlights

Market Capitalization
85.0M
Book Value
$2.21
Earnings Per Share (EPS)
-1.66
PEG Ratio
-0.13
Wall Street Target Price
1.8
Profit Margin
0.0%
Operating Margin TTM
-321.88%
Return On Assets TTM
-29.81%
Return On Equity TTM
-60.94%
Revenue TTM
21.4M
Revenue Per Share TTM
0.31
Quarterly Revenue Growth YOY
-51.2%
Gross Profit TTM
-60.0M
EBITDA
-84.4M
Diluted Eps TTM
-1.66
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.61
EPS Estimate Next Year
-1.17
EPS Estimate Current Quarter
-0.48
EPS Estimate Next Quarter
-0.48

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Aclaris Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
13
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 51.26%

Current $1.19
Target $1.80

Company Financials

FY17Y/Y Change
Revenue
1.7M
-
Net Income
-68.5M
↑ 42.52%
Net Profit Margin
-4.1K%
-
FY18Y/Y Change
Revenue
10.1M
↑ 499.58%
Net Income
-132.7M
↑ 93.71%
Net Profit Margin
-1.3K%
↑ 2756.07%
FY19Y/Y Change
Revenue
4.2M
↓ 58.11%
Net Income
-142.9M
↑ 7.62%
Net Profit Margin
-3.4K%
↓ 2064.06%
FY20Y/Y Change
Revenue
6.5M
↑ 53.35%
Net Income
-51.2M
↓ 64.19%
Net Profit Margin
-789.17%
↑ 2590.3%
FY21Y/Y Change
Revenue
6.8M
↑ 4.3%
Net Income
-114.3M
↑ 123.41%
Net Profit Margin
-1.7K%
↓ 901.13%
FY22Y/Y Change
Revenue
29.8M
↑ 340.05%
Net Income
-88.7M
↓ 22.42%
Net Profit Margin
-298.0%
↑ 1392.3%
Q2 FY22Q/Q Change
Revenue
1.5M
↑ 5.16%
Net Income
-16.7M
↓ 4.58%
Net Profit Margin
-1.1K%
↑ 111.44%
Q3 FY22Q/Q Change
Revenue
19.0M
↑ 1144.63%
Net Income
-21.2M
↑ 27.35%
Net Profit Margin
-111.63%
↑ 979.34%
Q4 FY22Q/Q Change
Revenue
7.8M
↓ 59.23%
Net Income
-33.3M
↑ 56.81%
Net Profit Margin
-429.4%
↓ 317.77%
Q1 FY23Q/Q Change
Revenue
2.5M
↓ 67.39%
Net Income
-26.4M
↓ 20.69%
Net Profit Margin
-1.0K%
↓ 614.98%
Q2 FY23Q/Q Change
Revenue
1.9M
↓ 26.07%
Net Income
-29.6M
↑ 12.0%
Net Profit Margin
-1.6K%
↓ 537.7%
Q3 FY23Q/Q Change
Revenue
9.3M
↑ 396.63%
Net Income
-29.3M
↓ 1.04%
Net Profit Margin
-315.24%
↑ 1266.84%
FY17Y/Y Change
Total Assets
243.5M
↑ 38.29%
Total Liabilities
18.2M
↑ 176.68%
FY18Y/Y Change
Total Assets
275.6M
↑ 13.16%
Total Liabilities
60.4M
↑ 231.24%
FY19Y/Y Change
Total Assets
98.3M
↓ 64.33%
Total Liabilities
28.4M
↓ 53.04%
FY20Y/Y Change
Total Assets
70.8M
↓ 27.99%
Total Liabilities
33.1M
↑ 16.73%
FY21Y/Y Change
Total Assets
251.2M
↑ 254.9%
Total Liabilities
53.9M
↑ 62.58%
FY22Y/Y Change
Total Assets
254.6M
↑ 1.35%
Total Liabilities
57.0M
↑ 5.76%
Q2 FY22Q/Q Change
Total Assets
278.0M
↑ 22.71%
Total Liabilities
42.2M
↓ 8.86%
Q3 FY22Q/Q Change
Total Assets
267.6M
↓ 3.72%
Total Liabilities
47.8M
↑ 13.19%
Q4 FY22Q/Q Change
Total Assets
254.6M
↓ 4.87%
Total Liabilities
57.0M
↑ 19.21%
Q1 FY23Q/Q Change
Total Assets
229.7M
↓ 9.78%
Total Liabilities
52.9M
↓ 7.16%
Q2 FY23Q/Q Change
Total Assets
235.6M
↑ 2.59%
Total Liabilities
55.9M
↑ 5.68%
Q3 FY23Q/Q Change
Total Assets
218.4M
↓ 7.34%
Total Liabilities
62.0M
↑ 10.95%
FY17Y/Y Change
Operating Cash Flow
-54.7M
↑ 57.97%
Investing Cash Flow
-55.7M
↓ 10.03%
Financing Cash Flow
100.4M
↓ 14.07%
FY18Y/Y Change
Operating Cash Flow
-100.8M
↑ 84.42%
Investing Cash Flow
9.4M
↓ 116.82%
Financing Cash Flow
128.3M
↑ 27.77%
FY19Y/Y Change
Operating Cash Flow
-96.4M
↓ 4.33%
Investing Cash Flow
105.7M
↑ 1028.21%
Financing Cash Flow
-30.3M
↓ 123.64%
FY20Y/Y Change
Operating Cash Flow
-38.6M
↓ 59.94%
Investing Cash Flow
6.4M
↓ 93.96%
Financing Cash Flow
18.4M
↓ 160.6%
FY21Y/Y Change
Operating Cash Flow
-52.1M
↑ 34.95%
Investing Cash Flow
-167.6M
↓ 2724.58%
Financing Cash Flow
225.1M
↑ 1124.97%
FY22Y/Y Change
Operating Cash Flow
-67.6M
↑ 29.6%
Investing Cash Flow
12.6M
↓ 107.53%
Financing Cash Flow
72.9M
↓ 67.62%
Q2 FY22Q/Q Change
Operating Cash Flow
-19.7M
↓ 6.21%
Investing Cash Flow
-21.2M
↓ 170.9%
Financing Cash Flow
72.8M
↑ 242603.33%
Q3 FY22Q/Q Change
Operating Cash Flow
-7.8M
↓ 60.25%
Investing Cash Flow
1.2M
↓ 105.73%
Financing Cash Flow
-11.0K
↓ 100.02%
Q4 FY22Q/Q Change
Operating Cash Flow
-19.1M
↑ 144.53%
Investing Cash Flow
2.7M
↑ 122.02%
Financing Cash Flow
37.0K
↓ 436.36%
Q1 FY23Q/Q Change
Operating Cash Flow
-26.4M
↑ 37.87%
Investing Cash Flow
25.8M
↑ 854.77%
Financing Cash Flow
26.7M
↑ 72181.08%
Q2 FY23Q/Q Change
Operating Cash Flow
-20.7M
↓ 21.63%
Investing Cash Flow
-19.7M
↓ 176.22%
Financing Cash Flow
26.7M
↑ 0.0%
Q3 FY23Q/Q Change
Operating Cash Flow
-24.6M
↑ 18.9%
Investing Cash Flow
32.5M
↓ 265.47%
Financing Cash Flow
-87.0K
↓ 100.33%

Technicals Summary

Sell

Neutral

Buy

Aclaris Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aclaris Therapeutics Inc
Aclaris Therapeutics Inc
-4.8%
-82.75%
-90.18%
-94.39%
-81.89%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
10.31%
16.97%
23.09%
11.19%
174.29%
Agilent Technologies Inc.
Agilent Technologies Inc.
1.66%
10.32%
-7.14%
8.13%
66.41%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
4.92%
4.27%
4.32%
25.08%
122.47%
Danaher Corp.
Danaher Corp.
11.63%
-0.66%
2.38%
15.77%
106.12%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
14.74%
12.9%
18.37%
28.41%
74.41%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aclaris Therapeutics Inc
Aclaris Therapeutics Inc
NA
NA
-0.13
-1.61
-0.61
-0.3
NA
2.21
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
56.85
56.85
5.45
11.14
0.81
0.23
NA
17.87
Agilent Technologies Inc.
Agilent Technologies Inc.
32.28
32.28
2.54
5.49
0.22
0.08
0.01
20.01
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
36.23
36.23
2.78
21.56
0.13
0.05
0.0
120.73
Danaher Corp.
Danaher Corp.
44.65
44.65
3.29
7.04
0.08
0.04
0.0
72.36
Iqvia Holdings Inc.
Iqvia Holdings Inc.
32.59
32.59
1.57
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aclaris Therapeutics Inc
Aclaris Therapeutics Inc
Buy
$85.0M
-81.89%
NA
0.0%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$47.4B
174.29%
56.85
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.7B
66.41%
32.28
18.15%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$216.6B
122.47%
36.23
13.99%
Danaher Corp.
Danaher Corp.
Buy
$186.9B
106.12%
44.65
19.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$44.9B
74.41%
32.59
9.06%

Institutional Holdings

  • Bvf Inc

    9.97%
  • BlackRock Inc

    7.92%
  • RA Capital Management, LLC

    6.21%
  • Rock Springs Capital Management LP

    5.59%
  • Bain Capital Life Sciences Investors, LLC

    4.80%
  • Vanguard Group Inc

    4.75%

Corporate Announcements

  • Aclaris Therapeutics Inc Earnings

    Aclaris Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.

Organization
Aclaris Therapeutics Inc
Employees
100
CEO
Dr. Neal S. Walker D.O., M.D.
Industry
Health Technology

FAQs